Even after today’s bounce, UBX is down 92% from its 2018 IPO (#msg-140490600). DME and AMD are huge markets, but there’s now competition from biosimilars to the anti-VEGF drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.